실적분석 2026년 8월 5일

Eli Lilly ($LLY) Q2 2026 Earnings Analysis — Revenue and Adjusted EPS Significantly Beat Estimates; Full-Year Revenue Guidance Raised

Earnings Scorecard

Revenue: $22.974 billion (+48% YoY vs. $15.558 billion prior year, estimate $20.686 billion) ✅ Beat

EPS: Adjusted $8.38 (+33% YoY vs. $6.31 prior year, estimate $6.58) ✅ Beat

Guidance: Raised — 2026 full-year revenue $85–$87 billion (prior $82–$85 billion); adjusted EPS $35.50–$36.50 (midpoint of underlying business raised by $2.78, offset by $3.03 of acquisition-related costs)

Stock Reaction: Extended hours +4.75% ($1,168.66) — as of 08-05 20:45 KST

Positives

Revenue beat by wide margin: Q2 revenue of $22.974 billion significantly exceeded the $20.686 billion estimate.

Adjusted EPS beat: Adjusted EPS of $8.38 topped the $6.58 estimate.

Growth in obesity and diabetes franchises: Mounjaro posted $9.943 billion (+91%) and Zepbound $4.928 billion (+46%).

Q2 global revenue reached $22.974 billion, up 48% from $15.558 billion a year earlier, with a 60% increase in volume driving the growth. Key product franchise revenue reached $15.7 billion, and revenue from key products in the immunology, oncology, and neuroscience therapeutic areas rose 121% YoY.

Flagship Mounjaro generated $9.943 billion in global revenue (+91% YoY), with ex-US sales surging 172%, supporting international expansion. US sales of obesity therapy Zepbound climbed 44% to $4.928 billion, as strong demand offset the impact of price declines.

Adjusted EPS rose 33% YoY to $8.38 from $6.31, comfortably ahead of the $6.58 analyst estimate. The company raised its full-year revenue outlook to $85–$87 billion and also outlined the completion of the Phase 3 clinical data package for next-generation obesity therapy retatrutide and a plan to file for US approval in Q1 2027.

Negatives

Realized price declines: Global realized prices fell 13%, partially eroding the volume-driven gains.

Heavy acquisition-related costs: Approximately $2.78 billion of acquired in-process R&D ($3.03 per share) weighed on earnings.

International pricing pressure: Ex-US realized prices dropped 36%, heavily impacted by China's national reimbursement listing.

While volume fueled revenue growth, prices moved in the opposite direction. Global realized prices fell 13% — down 3% in the US (approximately 9% excluding adjustments to estimated sales rebates and discounts) and down 36% outside the US. The inclusion of Mounjaro on China's national reimbursement drug list was cited as the main driver behind the international price decline.

Acquired in-process R&D recognized in Q2 surged to $2.776 billion from $154 million a year earlier, with a $3.03 per-share charge flowing through both GAAP and adjusted EPS. An additional $703 million in special charges tied to acquisition- and integration-related asset impairments and restructuring was also reflected.

As a result, the adjusted EPS guidance for the underlying business was raised by $2.78 at the midpoint, but acquisition-related costs of $3.03 offset that gain, leaving the final full-year adjusted EPS guidance range at $35.50–$36.50. The results themselves were strong, but pricing pressure and large acquisition costs will remain variables to watch when assessing earnings quality going forward.

What the Company Said

Chairman and CEO David A. Ricks emphasized that growth momentum continues, citing the 48% revenue growth and the raised full-year outlook. He also highlighted the completed clinical data package for next-generation weight loss therapy retatrutide, the expansion of manufacturing capacity, and new assets flowing in through business development as brightening the company's future.

The full-year outlook lifted both revenue and operating margin, while the adjusted EPS guidance reflects a structure in which Q2 acquisition-related costs outweigh the upgrade to the underlying business. The market appears to have placed greater weight on the message that demand remains strong and the company has once again raised its growth visibility, rather than on the headline numbers alone. The US filing of oral diabetes/weight loss therapy Foundry (orforglipron) for the diabetes indication, global regulatory preparation for retatrutide in obesity, and the announcement of an additional $4.5 billion investment in Indiana manufacturing facilities were read as further bolstering the medium- to long-term growth narrative.

Market Reaction and Key Points Ahead

The market appears to have read the revenue and adjusted EPS beats, the raised full-year revenue guidance, and continued Mounjaro and Zepbound demand as a single package. Despite the more than $3 per-share acquisition-related R&D charge dragging on earnings, the size of the beat and progress in the drug pipeline translated into relief buying. The extended-hours reaction shown on the scorecard reflects these expectations being immediately priced into the stock.

It remains to be seen in Q3 whether Mounjaro and Zepbound volume growth will continue to offset price declines.

Watch the tone of the company's guidance updates to see whether the full-year adjusted EPS outlook can be held without additional acquired in-process R&D charges.

The retatrutide approval timeline (Q1 2027 filing target) and regulatory progress for oral Foundry will be central to medium- to long-term stock valuation.